Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Endocrinology
•
Bone and Calcium Disorders
Under what circumstances would you choose palopegteriparatide over teriparatide in patients with chronic hypoparathyroidism?
Related Questions
Does vitamin D supplementation in primary hyperparathyroidism increase the risk of kidney stones?
How long should a patient be treated with a bisphosphonate after a course of an anabolic medication has been completed?
What treatment options are there for Fanconi syndrome-induced osteoporosis in young female patients outside of electrolyte and mineral replacement?
Can you use bisphosphonates in a patient with osteoporosis who has had prior avascular necrosis of TMJ due to steroid use?
Is there a role for calcitriol in dialysis patients regardless of PTH level?
How would you approach a finding of osteoporosis (Z score -4.5) in a recently postpartum patient who had DEXA sent for long-term low-dose glucocorticoid use?
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
What is your approach to managing symptomatic primary hyperparathyroidism in the third trimester of pregnancy?
Which fracture sites outside of the classical spine and hip are considered to be osteoporotic fractures even in the absence of a bone density diagnosis?
Do you recommend a particular antiresorptive/anabolic agent for patients who are at high risk for fractures but have high risk of osteonecrosis of the jaw?
